These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 31265453)

  • 1. Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network.
    Grosset AA; Ouellet V; Caron C; Fragoso G; Barrès V; Delvoye N; Latour M; Aprikian A; Bergeron A; Chevalier S; Fazli L; Fleshner N; Gleave M; Karakiewicz P; Lacombe L; Lattouf JB; van der Kwast T; Trudel D; Mes-Masson AM; Saad F;
    PLoS Med; 2019 Jul; 16(7):e1002847. PubMed ID: 31265453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer.
    Gannon PO; Lessard L; Stevens LM; Forest V; Bégin LR; Minner S; Tennstedt P; Schlomm T; Mes-Masson AM; Saad F
    Eur J Cancer; 2013 Jul; 49(10):2441-8. PubMed ID: 23541563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation.
    Ouellet V; Aprikian A; Bergeron A; Brimo F; Bristow RG; Chevalier S; Drachenberg D; Fazli L; Fleshner NE; Gleave M; Karakiewicz P; Klotz L; Lacombe L; Lattouf JB; van der Kwast T; Squire JA; Latour M; Trudel D; Mes-Masson AM; Saad F
    BMC Urol; 2018 Sep; 18(1):78. PubMed ID: 30200929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
    Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
    Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients.
    Schmidt L; Fredsøe J; Kristensen H; Strand SH; Rasmussen A; Høyer S; Borre M; Mouritzen P; Ørntoft T; Sørensen KD
    Ann Oncol; 2018 Sep; 29(9):2003-2009. PubMed ID: 30010760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The inflammation-related biomarker CXCR7 independently predicts patient outcome after radical prostatectomy.
    Bargão Santos P; Lobo J; Félix A; Silva F; Manso RT; Costa JO; Lourenço B; Sequeira JP; Jerónimo C; Patel HHR; Henrique R
    Urol Oncol; 2020 Oct; 38(10):794.e17-794.e27. PubMed ID: 32278731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
    Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
    Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Cross-Talk between Alternative and Classical NF-κB Pathways in Prostate Cancer Tissues as Measured by a Multi-Staining Immunofluorescence Co-Localization Assay.
    Labouba I; Le Page C; Communal L; Kristessen T; You X; Péant B; Barrès V; Gannon PO; Mes-Masson AM; Saad F
    PLoS One; 2015; 10(7):e0131024. PubMed ID: 26186215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse.
    Domingo-Domenech J; Mellado B; Ferrer B; Truan D; Codony-Servat J; Sauleda S; Alcover J; Campo E; Gascon P; Rovira A; Ross JS; Fernández PL; Albanell J
    Br J Cancer; 2005 Nov; 93(11):1285-94. PubMed ID: 16278667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer.
    Rhodes DR; Sanda MG; Otte AP; Chinnaiyan AM; Rubin MA
    J Natl Cancer Inst; 2003 May; 95(9):661-8. PubMed ID: 12734317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear Shape and Architecture in Benign Fields Predict Biochemical Recurrence in Prostate Cancer Patients Following Radical Prostatectomy: Preliminary Findings.
    Lee G; Veltri RW; Zhu G; Ali S; Epstein JI; Madabhushi A
    Eur Urol Focus; 2017 Oct; 3(4-5):457-466. PubMed ID: 28753763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
    Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
    Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of serum response factor expression in prostate cancer biochemical recurrence.
    Prencipe M; Fabre A; Murphy TB; Vargyas E; O'Neill A; Bjartell A; Tasken KA; Grytli HH; Svindland A; Berge V; Eri LM; Gallagher W; Watson RW
    Prostate; 2018 Jul; 78(10):724-730. PubMed ID: 29608018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic silencing of MEIS2 in prostate cancer recurrence.
    Nørgaard M; Haldrup C; Bjerre MT; Høyer S; Ulhøi B; Borre M; Sørensen KD
    Clin Epigenetics; 2019 Oct; 11(1):147. PubMed ID: 31640805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD10 is inversely associated with nuclear factor-kappa B and predicts biochemical recurrence after radical prostatectomy.
    Voutsadakis IA; Vlachostergios PJ; Daliani DD; Karasavvidou F; Kakkas G; Moutzouris G; Melekos MD; Papandreou CN
    Urol Int; 2012; 88(2):158-64. PubMed ID: 22286396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.
    Gevensleben H; Holmes EE; Goltz D; Dietrich J; Sailer V; Ellinger J; Dietrich D; Kristiansen G
    Oncotarget; 2016 Nov; 7(48):79943-79955. PubMed ID: 27835597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy.
    Hamid AA; Gray KP; Huang Y; Bowden M; Pomerantz M; Loda M; Sweeney CJ
    Eur Urol Oncol; 2019 Sep; 2(5):475-482. PubMed ID: 31411988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis.
    Diallo JS; Aldejmah A; Mouhim AF; Fahmy MA; Koumakpayi IH; Sircar K; Bégin LR; Mes-Masson AM; Saad F
    BJU Int; 2008 May; 101(10):1302-9. PubMed ID: 18294307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer.
    Fradet V; Lessard L; Bégin LR; Karakiewicz P; Masson AM; Saad F
    Clin Cancer Res; 2004 Dec; 10(24):8460-4. PubMed ID: 15623625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
    Li T; Gui Y; Yuan T; Liao G; Bian C; Jiang Q; Huang S; Liu B; Wu D
    BJU Int; 2012 Dec; 110(11 Pt C):E1125-30. PubMed ID: 22672360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.